Grail Inc
NASDAQ:GRAL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Grail Inc
NASDAQ:GRAL
|
US |
Grail Inc
Grail Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Menlo Park, California and currently employs 1,370 full-time employees. The company went IPO on 2024-06-12. GRAIL, Inc., formerly GRAIL, LLC, is a healthcare company, which is engaged in saving lives and shifting the paradigm in early cancer detection. The company is focused on alleviating the global burden of cancer by using next-generation sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its products include Galleri and Beyond. The Galleri test is a commercially available screening test for early detection of multiple types of cancer, which is termed multi-cancer early detection (MCED). Galleri screening test results can help guide next steps for a diagnosis of cancer by healthcare providers.
Grail Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Menlo Park, California and currently employs 1,370 full-time employees. The company went IPO on 2024-06-12. GRAIL, Inc., formerly GRAIL, LLC, is a healthcare company, which is engaged in saving lives and shifting the paradigm in early cancer detection. The company is focused on alleviating the global burden of cancer by using next-generation sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its products include Galleri and Beyond. The Galleri test is a commercially available screening test for early detection of multiple types of cancer, which is termed multi-cancer early detection (MCED). Galleri screening test results can help guide next steps for a diagnosis of cancer by healthcare providers.
Strong Revenue Growth: GRAIL reported fourth quarter revenue of $43.6 million, up 14% year-over-year, and full year 2025 revenue of $147.2 million, a 17% increase.
Test Volume & Prescribers: U.S. Galleri test volume grew 36% to over 185,000 tests in 2025; prescriber base rose 30% to approximately 17,000 providers.
Clinical Trial Results: NHS Galleri trial did not meet the primary endpoint of statistically significant reduction in late-stage cancers, but showed favorable trends, a fourfold increase in detection rate, and over 20% reduction in Stage IV diagnoses for certain cancers.
PMA Submission & Medicare Pathway: Completed FDA premarket approval (PMA) submission for Galleri; new federal law now enables Medicare coverage for FDA-approved multi-cancer early detection tests.
Financial Position & Guidance: Ended the year with $904.4 million in cash and reiterated 2026 Galleri sales growth guidance of 22% to 32%, with cash burn expected to be no more than $300 million.
Expansion Plans: Announced expansion of field sales and medical teams following strong study results and ongoing commercial momentum.
